The average analyst price target is $143.40 for this biotech stock—75% higher than where the shares are currently trading.
GW Pharmaceuticals (GWPH)
from Green Chip Stocks
While we’re in GW Pharmaceuticals (GWPH) for the long-haul, I can’t ignore the recent dip. GWPH has fallen below $85.00 a share. Nothing has changed with the company, and its pipeline of cannabis-based treatments, specifically for epilepsy, is strong. It currently has four epilepsy clinical trials under way in Phase III.
Bottom line: In terms of cannabis-based treatments for epilepsy, its way ahead of any of its competitors.
Motley Fool recently did a negative piece on the company. Not sure if that had any effect or not, but right now, the average price target from analysts is $139.59. The highest price targets come from Piper Jaffray ($147), and Morgan Stanley ($150). I’m a bit more conservative at $136.
In any event, if you’re not in now, but you were looking to trade GWPH, these levels are very appealing. For the purposes of a quick trade, however, don’t pay more than $85.
Jeff Siegel, Green Chip Stocks, www.angelpub.com, 877-303-4529, October 19, 2015